brazilsfe.blogspot.com/2024/11/blog...
The Top Sponsors in Rare Diseases Clinical Trials Initiations
✔ Brazil SFE®
#Roche #AstraZeneca #Merck #BristolMyersSquibb #Pfizer #HengruiPharma #SinoBiopharmaceutical #Novartis #AbbVie #Incyte #JohnsonandJohnson #Sanofi #EnsaiosClínicos
The Top Sponsors in Rare Diseases Clinical Trials Initiations
✔ Brazil SFE®
#Roche #AstraZeneca #Merck #BristolMyersSquibb #Pfizer #HengruiPharma #SinoBiopharmaceutical #Novartis #AbbVie #Incyte #JohnsonandJohnson #Sanofi #EnsaiosClínicos
The Top Sponsors in Rare Diseases Clinical Trials Initiations
✔ Brazil SFE® - André Luiz Bernardes
♕Data Science ✰BI, Big Data & Analytics, ✰Market Intelligence, ♕Sales Force Effectiveness...
brazilsfe.blogspot.com
December 24, 2024 at 10:11 AM
brazilsfe.blogspot.com/2024/11/blog...
The Top Sponsors in Rare Diseases Clinical Trials Initiations
✔ Brazil SFE®
#Roche #AstraZeneca #Merck #BristolMyersSquibb #Pfizer #HengruiPharma #SinoBiopharmaceutical #Novartis #AbbVie #Incyte #JohnsonandJohnson #Sanofi #EnsaiosClínicos
The Top Sponsors in Rare Diseases Clinical Trials Initiations
✔ Brazil SFE®
#Roche #AstraZeneca #Merck #BristolMyersSquibb #Pfizer #HengruiPharma #SinoBiopharmaceutical #Novartis #AbbVie #Incyte #JohnsonandJohnson #Sanofi #EnsaiosClínicos
[1/4] 2026-06-16 07:46:57 - [SinoBiopharmaceutical: TQC2938 (ST2 monoclonal antibody) announced phase II clinical data at EAACI 2026] SinoBiopharmaceutical announced on the Hong Kong Stock Exchange that TQC2938 (ST2 monoclonal antibody), a national category 1 innovative drug
June 15, 2026 at 11:55 PM
[1/4] 2026-06-16 07:46:57 - [SinoBiopharmaceutical: TQC2938 (ST2 monoclonal antibody) announced phase II clinical data at EAACI 2026] SinoBiopharmaceutical announced on the Hong Kong Stock Exchange that TQC2938 (ST2 monoclonal antibody), a national category 1 innovative drug
[1/4] 2026-06-16 07:46:57 - [SinoBiopharmaceutical: TQC2938 (ST2 monoclonal antibody) announced phase II clinical data at EAACI 2026] SinoBiopharmaceutical announced on the Hong Kong Stock Exchange that TQC2938 (ST2 monoclonal antibody), a national category 1 innovative drug
June 15, 2026 at 11:53 PM
[1/4] 2026-06-16 07:46:57 - [SinoBiopharmaceutical: TQC2938 (ST2 monoclonal antibody) announced phase II clinical data at EAACI 2026] SinoBiopharmaceutical announced on the Hong Kong Stock Exchange that TQC2938 (ST2 monoclonal antibody), a national category 1 innovative drug